Skip to Content

Lumigan Side Effects

Generic Name: bimatoprost ophthalmic

Note: This document contains side effect information about bimatoprost ophthalmic. Some of the dosage forms listed on this page may not apply to the brand name Lumigan.

In Summary

Common side effects of Lumigan include: increased growth in number of eyelashes. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to bimatoprost ophthalmic: ophthalmic solution

Along with its needed effects, bimatoprost ophthalmic (the active ingredient contained in Lumigan) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking bimatoprost ophthalmic:

Less Common

  • Blindness
  • bloody eye
  • blurred or decreased vision
  • change in color vision
  • color changes in the skin around the eyes
  • difficulty seeing at night
  • disturbed color perception
  • double vision
  • dry eyes
  • eye color changes
  • fever or chills
  • halos around lights
  • lack or loss of strength
  • loss of vision
  • night blindness
  • overbright appearance of lights
  • redness, burning, dry, or itching eyes
  • redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid
  • tunnel vision

Some side effects of bimatoprost ophthalmic may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

  • Body aches or pain
  • cough
  • difficulty with breathing
  • ear congestion
  • headache
  • loss of voice
  • nasal congestion
  • redness of the white part of eyes or inside of the eyelids
  • runny nose
  • sneezing
  • sore throat
  • unusual tiredness or weakness

Less Common

  • Darkening of the eyelashes
  • eye discharge or excessive tearing
  • eye strain
  • feeling of having something in the eye
  • increase in hair growth
  • increased sensitivity of the eyes to sunlight

For Healthcare Professionals

Applies to bimatoprost ophthalmic: ophthalmic solution

General

The most frequently reported adverse reactions were eyelash growth, conjunctival hyperemia, and ocular pruritus.[Ref]

Ocular

Very common (10% or more): Growth of eyelashes (up to 45%), conjunctival hyperemia (up to 44%), ocular pruritus (up to 15%)

Common (1% to 10%): Allergic conjunctivitis, asthenopia, blepharitis, blurred vision, cataract, conjunctival edema, conjunctival hemorrhage, corneal erosion, dry eye, eye discharge, eye irritation, eye pain, eye pruritus, eyelash darkening, eyelid pruritus, foreign body sensation, increased iris pigmentation, lacrimation increased, ocular burning, ocular dryness, ocular irritation, photophobia, punctate keratitis, superficial punctate keratitis, tearing, visual disturbance, worsening of visual acuity

Uncommon (0.1% to 1%): Blepharospasm, eyelid edema, eyelid margin crusting, eyelid retraction, iris hyperpigmentation, iritis, retinal hemorrhage, uveitis

Rare (0.01% to 0.1%): Corneal calcification

Frequency not reported: Blepharal pigmentation, cystoid macular edema, eye edema, eyelash changes, eyelid sulcus deepening, intraocular inflammation, macular edema, signs/symptoms of eye allergy

Postmarketing reports: Enophthalmos[Ref]

Corneal calcification occurred in patients with significant corneal damage using formulations containing phosphate.[Ref]

Dermatologic

Common (1% to 10%): Eyelid erythema, hirsutism, hypertrichosis, periocular skin hyperpigmentation, periorbital erythema, pigmentation of periocular skin, skin hyperpigmentation

Uncommon (0.1% to 1%): Abnormal hair growth, dry skin, madarosis, pruritus

Frequency not reported: Lid changes, periorbital changes, pigmentation, signs/symptoms of allergic dermatitis[Ref]

Immunologic

Common (1% to 10%): Colds, infections[Ref]

Respiratory

Common (1% to 10%): Upper respiratory tract infections

Frequency not reported: Asthma, asthma exacerbation, chronic obstructive pulmonary disease (COPD) exacerbation, dyspnea

Postmarketing reports: Asthma-like symptoms[Ref]

Nervous system

Common (1% to 10%): Headache

Uncommon (0.1% to 1%): Dizziness, vertigo[Ref]

Local

Common (1% to 10%): Instillation site irritation[Ref]

Hepatic

Common (1% to 10%): Abnormal liver function tests[Ref]

Other

Uncommon (0.1% to 1%): Asthenia[Ref]

Cardiovascular

Common (1% to 10%): Hypertension[Ref]

Gastrointestinal

Uncommon (0.1% to 1%): Nausea[Ref]

Psychiatric

Uncommon (0.1% to 1%): Depression[Ref]

Hypersensitivity

Frequency not reported: Hypersensitivity, hypersensitivity reaction[Ref]

References

1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. "Product Information. Lumigan (bimatoprost ophthalmic)" Allergan Inc, Irvine, CA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Hide